Is BEACOPP better than ABVD?

Current Hematologic Malignancy Reports

Volumn 2, Issue 3, 2007, Pages 161-166

  Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; VINCRISTINE;

AMENORRHEA; BONE MARROW SUPPRESSION; CANCER RISK; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; HODGKIN DISEASE; HUMAN; INFECTION; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FEMALE; FORECASTING; HODGKIN DISEASE; HUMANS; INFERTILITY; MALE; MULTICENTER STUDIES AS TOPIC; NEOPLASMS, SECOND PRIMARY; PATIENT SELECTION; PREDNISONE; PROCARBAZINE; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 34547727388     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-007-0022-2     Document Type: Review

References (36)

1. DeVita VT Jr, Serpick AA: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970, 73:881-895.
2. DeVita VT Jr, Simon RM, Hubbard SM, et al.: Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980, 92:587-595.
3. Santoro A, Bonfante V, Bonadonna G: Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 1982, 96:139-143.
4. Bonadonna G, Zucali R, Monfardini S, et al.: Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975, 36:252-259.
5. Santoro A, Bonadonna G, Bonfante V, Valagussa P: Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 1982, 306:770-775.
6. Canellos GP, Anderson JR, Propert KJ, et al.: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478-1484.
7. Bonadonna G, Valagussa P, Santoro A: Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann Intern Med 1986, 104:739-746.
8. Klimo P, Connors JM: MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 1985, 3:1174-1182.
9. Glick JH, Young ML, Harrington D, et al.: MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998, 16:19-26.
10. Duggan DB, Petroni GR, Johnson JL, et al.: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003, 21:607-614.
11. Diehl V, Sieber M, Rüffer U, et al.: BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 1997, 8:143-148.
12. Tesch H, Diehl V, Lathan B, et al.: Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood 1998, 92:4560-4567.
13. Diehl V, Franklin J, Pfreundschuh M, et al.: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003, 348:2386-2395.
14. Rüffer JU, Ballova V, Glossman J, et al: BEACOPP and COPP/ABVD as salvage treatments after primary extended field radiation therapy of early stage Hodgkin's disease - results of the German Hodgkin Study Group. Leuk Lymph 2005, 46:1561-1567.
15. Dann EJ, Bar-Shalom R, Tamir A, et al.: Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007, 109:905-909.
16. • Behringer K, Breuer K, Reineke T, et al.: Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005, 23:7555-7564. Despite its impressive activity, BEACOPP is associated with a number of adverse effects, including amenorrhea. This study demonstrates that the frequency is greater than with other available Hodgkin's regimens.
17. Josting A, Wiedenmann S, Franklin J, et al.: Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003, 21:3440-3446.
18. Behringer K, Josting A, Schiller P, et al.: Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 2004, 15:1079-1085.
19. Sieber M, Bredenfield H, Josting A, et al.: 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003, 21:1734-1739.
20. Engert A, Bredenfield H, Döhner H, et al.: Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. Haematologica 2006, 91:546-549.
21. Engert A, Franklin J, Mueller RP, et al.: HD12 randomized trial comparing 8 dose-escalated cycles of BEACOPP with 4 escalated and 4 baseline cycles in patients with advanced stage Hodgkin lymphoma (HL): an analysis of the German Hodgkin Lymphoma Study Group (GHSG) [abstract]. Blood 2006, 108(pt 1):33a (Abstract 99).
22. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998, 339:1506-1514.
23. Ballova V, Rüffer J-U, Haverkamp H, et al.: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005, 16:124-131.
24. Hartmann P, Rehwald U, Salzberger B, et al.: BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 2003, 14:1562-1569.
25. Canellos GP, Duggan D, Johnson J, Niedzwiecki D: How important is bleomycin in the Adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 2004, 22:1532-1533.
26. Martin WG, Ristow KM, Habermann TM, et al.: Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005, 23:7614-7620.
27. Santoro A, Devizzi L, Bonfante V, et al.: Phase II study with gemcitabine in pretreated patients with Hodgkin's (HD) and non-Hodgkin's lymphomas (NHL): results of a multicenter study [abstract]. Proc Am Soc Clin Oncol 1997, 16:21a (Abstract 71).
28. Tesch H, Santoro A, Fiedler F, et al.: Phase II study of gemcitabine in pretreated Hodgkin's disease: results of a multicenter study [abstract]. Blood 1997, 90(suppl 1):339a (Abstract 1514).
29. • Bredenfield H, Franklin J, Nogova L, et al.: Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2004, 22:2424-2429. New regimens are needed in Hodgkin's lymphoma to improve long-term outcome by increasing efficacy and reducing toxicity. Gemcitabine, a drug highly active in Hodgkin's lymphoma, was incorporated into BEACOPP, but the pulmonary complications of combining this agent with bleomycin were prohibitive.
30. Friedberg JW, Neuberg D, Kim H, et al.: Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin's disease: unacceptable acute pulmonary toxicity. Cancer 2003, 98:978-982.
31. Bartlett N, Niedzwiecki D, Johnson J, et al.: Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007, In press.
32. Hutchings M, Loft A, Hansen M, et al.: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107:52-59.
33. •• Cheson BD, Pfistner B, Juweid ME, et al.: Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586. Standardized response criteria are essential for the conduct of clinical trials. The International Harmonization Project developed recommendations for incorporation of new technologies (most importantly, PET) into the previous International Working Group Criteria. These criteria will allow for more accurate response assessment and comparison among clinical trials in lymphoma.
34. Sanchez-Aguilera A, Montalban C, de la Cueva P, et al.: Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006, 108:662-668.
35. Diehl V, Brillant C, Engert A, et al.: Recent interim analysis of the HD11 trial of the GHSG: intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin's lymphoma [abstract]. Blood 2005, 106:816a.
36. Fuchs M, Diehl V, Re D: Current strategies and new approaches in the treatment of Hodgkin's lymphoma [review]. Pathobiology 2006, 73:126-140.